Merck KgaA's Daejeon, South Korea life science production site (Credit: Merck KgaA website)
April 3, 2024 12:00 PM EDT
Manufacturing

As Mer­ck KGaA grows South Ko­re­an foot­print, it al­so ze­roes in on re­gion­al man­u­fac­tur­ing

Anna Brown

News Reporter

Mer­ck KGaA is look­ing to fur­ther boost its ca­pac­i­ty in South Ko­rea as bio­phar­ma com­pa­nies eye to lo­cal­ize pro­duc­tion and tight­en their sup­ply chains in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times